CN Patent

CN119173514A — 作为jak2 v617f抑制剂的三环脲化合物

Assigned to Incyte Corp · Expires 2024-12-20 · 1y expired

What this patent protects

本申请提供了调节JAK2的V617F变体的活性的三环脲化合物，所述化合物可用于治疗各种疾病，包括癌症。

USPTO Abstract

本申请提供了调节JAK2的V617F变体的活性的三环脲化合物，所述化合物可用于治疗各种疾病，包括癌症。

Drugs covered by this patent

Patent Metadata

Patent number
CN119173514A
Jurisdiction
CN
Classification
—
Expires
2024-12-20
Drug substance claim
No
Drug product claim
No
Assignee
Incyte Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.